Mutations in the EGFR gene, including a small in-frame deletion in exon 19 and L858R point mutation in exon 21, accounted for 85–95% of EGFRM NSCLC patients who responded to EGFR-TKIs [2,3,5]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.